GRM2 eta GRM3 geneen adierazpenaren ebaluazioa subjektu eskizofrenikoen postmortem garuneko kortex aurrefrontalean

Abstract

mGluR2/3 activating drugs have been tested to treat glutamatergic dysfunction in schizophrenia with poor efficacy, possibly due to mGluR2 depletion caused by clozapine or other antipsychotics. Gene expression of GRM2 and GRM3, which encode mGluR2/3, was measured by qPCR in postmortem brain prefrontal cortex. The effect of antipsychotic treatment, and specially clozapine, was evaluated in schizophrenic subjects treated or not-treated with these drugs. No differences were found in the gene expression of GRM2 and GRM3 between schizophrenic and control subjects. Clozapine did not significantly modulate GRM2/3 gene expression compared to other antipsychotics. Reduced transcription of GRM2 does not explain reduced mGluR2 receptor density.